<code id='3880169313'></code><style id='3880169313'></style>
    • <acronym id='3880169313'></acronym>
      <center id='3880169313'><center id='3880169313'><tfoot id='3880169313'></tfoot></center><abbr id='3880169313'><dir id='3880169313'><tfoot id='3880169313'></tfoot><noframes id='3880169313'>

    • <optgroup id='3880169313'><strike id='3880169313'><sup id='3880169313'></sup></strike><code id='3880169313'></code></optgroup>
        1. <b id='3880169313'><label id='3880169313'><select id='3880169313'><dt id='3880169313'><span id='3880169313'></span></dt></select></label></b><u id='3880169313'></u>
          <i id='3880169313'><strike id='3880169313'><tt id='3880169313'><pre id='3880169313'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:67
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          Can medical device makers keep up in the race to treat obesity?
          Can medical device makers keep up in the race to treat obesity?

          KatyLemayforSTATThemakersofminimallyinvasivesurgicaldevicesseemedpoisedtocaptureawideswathoftheobesi

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Report cites 'urgent' need to recruit more diverse clinical trial participants

          AdobeThepersistentlackofdiversityamongparticipantsinclinicaltrialsisacriticalissuethatisharmingbothp